Novel Ribostamycins and SAR Study of Ring III Aminosugar
新型核霉素和环III氨基糖的SAR研究
基本信息
- 批准号:7195772
- 负责人:
- 金额:$ 13.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-03-01 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcidsAffinityAmerican Type Culture CollectionAmikacinAmino AcidsAmino SugarsAminoglycoside AntibioticsAminoglycoside resistanceAminoglycosidesAnthrax diseaseAnti-Bacterial AgentsAntibioticsAntifungal AgentsAntineoplastic AgentsAntiviral AgentsAreaBacillus (bacterium)Bacillus subtilisBacteriaBindingBinding SitesBiologicalBiological AssayCarbohydratesCellsChargeCollaborationsCoupledDeoxy SugarsDevelopmentDrug DesignDrug resistanceDrug-sensitiveEnterococcus faecalisEnzymesEscherichia coliEvaluationFluorescenceFutureGentamicinsGoalsHIVHybridsIn VitroKnowledgeLaboratoriesLeadLearningLibrariesMethodsModificationMultiple drug resistant Mycobacteria TuberculosisMycobacterium smegmatisMycobacterium tuberculosisNational SecurityNeomycinObject AttachmentOligopeptidesPhasePreparationProtocols documentationPublic HealthPyranmycinRNARangeResearchResearch PersonnelResistanceRibosomal RNARibostamycinRoentgen RaysSamplingScreening procedureServicesSolidStaphylococcus aureusStreptomycinStructureStructure-Activity RelationshipTestingWorkantibiotic designantimicrobialbacterial resistancebasecarbohydrate receptorcostcytotoxicitydesignexperienceimprovedin vivointerestnovelpathogenpractical applicationpyranosesugar
项目摘要
DESCRIPTION (provided by applicant): Carbohydrate research can contribute profound impacts in various fields although the synthesis of carbohydrate derivatives has been the major obstacle that impedes the progress in this area. Through our experience and effort, we have achieved our preliminary projected goals: synthesis of aminosugars/deoxysugars library, preparation of aminosugars/deoxysugars containing molecules with practical applications, and the studies of biological implications with these aminosugars/deoxysugars containing molecules. We are one of the few groups capable of creating such diverse unusual sugar and aminoglycoside libraries. After successfully achieving our initial goal of generating aminosugar/deoxysugar library, we have moved into one of the envisioned applications of unusual sugars: synthesizing a library of pyranmycin, novel aminoglycoside antibiotics. Compared to previous work, our pyranmycin designs provide the only examples with antibacterial activity close to neomycin (low micromole), and with much-improved acid stability. The later may potentially lead to the reduction of the cytotoxicity known to be associated with aminoglycoside antibiotics. Using synthetic approaches, we intend to synthesize two more structural entities coupled with a solid phase parallel synthesis of oligopeptides for the development of the general aminoglycoside designs against various strains of resistant bacteria, and with lower cytotoxicity. These are very challenging but interesting and important tasks. We have proposed several practical synthetic methods for our objectives. We have established our own facilities or collaborations for evaluating the antibacterial activity of our pyranmycin constructs in vivo and in whole cell based. We have learned solid knowledge in carbohydrate synthesis and aminoglycoside antibiotic design through our research. We wish to learn more regarding the influence of modulating the interactions, charge-charge and van der Waals, and apply the finding for future drug designs. It is our conviction that our proposed research will provide breakthroughs in carbohydrate-related fields, and pave the way to a broader research ranging from basic scientific studies like carbohydrates and receptors interaction to practical applications regarding the issues of public health and national security, such as, the development of clinically important unusual sugar-containing antibacterial (against anthrax, MDR-TB), antiviral (against HIV), antifungal, and anticancer agents.
描述(由申请人提供):碳水化合物研究可以在各个领域产生深远的影响,尽管碳水化合物衍生物的合成一直是阻碍该领域进步的主要障碍。通过我们的经验和努力,我们实现了我们的初步投影目标:氨基糖/脱氧糖库的综合,准备具有实际应用的分子的氨基糖/脱氧糖,以及使用这些氨基糖/脱氧糖的生物学含义的研究。我们是能够创建如此不同寻常的糖和氨基糖苷库的少数小组之一。在成功实现了产生氨基加糖/脱氧库库的最初目标之后,我们进入了一种不寻常的糖的设想应用之一:合成pyranmycin库,新型氨基糖苷抗生素。与以前的工作相比,我们的吡喃霉素设计提供了唯一的抗菌活性的例子,接近新霉素(低微孔),并且具有重大改良的酸稳定性。后期可能导致降低已知与氨基糖苷抗生素有关的细胞毒性。使用合成方法,我们打算合成两个又有两个结构实体,并结合寡肽的固相平行合成,以开发一般的氨基糖苷设计,以针对各种抗性细菌的菌株和较低的细胞毒性。这些非常具有挑战性,但有趣而重要的任务。我们已经为我们的目标提出了几种实用的合成方法。我们已经建立了自己的设施或协作,以评估体内和整个细胞中的pyranmycin构建体的抗菌活性。通过我们的研究,我们已经学习了碳水化合物合成和氨基糖苷抗生素设计的坚实知识。我们希望了解有关调节相互作用,电荷收费和范德华的影响的更多信息,并将其应用于未来的药物设计。 It is our conviction that our proposed research will provide breakthroughs in carbohydrate-related fields, and pave the way to a broader research ranging from basic scientific studies like carbohydrates and receptors interaction to practical applications regarding the issues of public health and national security, such as, the development of clinically important unusual sugar-containing antibacterial (against anthrax, MDR-TB), antiviral (against HIV),抗真菌和抗癌药。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHENG-WEI T CHANG其他文献
CHENG-WEI T CHANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHENG-WEI T CHANG', 18)}}的其他基金
Novel Ribostamycins and SAR Study of Ring III Aminosugar
新型核霉素及环III氨基糖的SAR研究
- 批准号:
7023762 - 财政年份:2004
- 资助金额:
$ 13.18万 - 项目类别:
Novel Ribostamycins and SAR Study of Ring III Aminosugar
新型核霉素及环III氨基糖的SAR研究
- 批准号:
6861100 - 财政年份:2004
- 资助金额:
$ 13.18万 - 项目类别:
Novel Ribostamycins and SAR Study of Ring III Aminosugar
新型核霉素和环III氨基糖的SAR研究
- 批准号:
7340550 - 财政年份:2004
- 资助金额:
$ 13.18万 - 项目类别:
Novel Ribostamycins and SAR Study of Ring III Aminosugar
新型核霉素及环III氨基糖的SAR研究
- 批准号:
6770744 - 财政年份:2004
- 资助金额:
$ 13.18万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Transformed Probiotic Bacteria for Treatment of Chronic Diseases
用于治疗慢性疾病的转化益生菌
- 批准号:
7431222 - 财政年份:2007
- 资助金额:
$ 13.18万 - 项目类别:
Nucleic acid-binding properties of human low density lipoprotein
人低密度脂蛋白的核酸结合特性
- 批准号:
7290032 - 财政年份:2007
- 资助金额:
$ 13.18万 - 项目类别:
Nucleic acid-binding properties of human low density lipoprotein
人低密度脂蛋白的核酸结合特性
- 批准号:
7477782 - 财政年份:2007
- 资助金额:
$ 13.18万 - 项目类别:
Drew MIDARP (Infrastructure in Drug Abuse Research)
Drew MIDARP(药物滥用研究基础设施)
- 批准号:
7494900 - 财政年份:2004
- 资助金额:
$ 13.18万 - 项目类别: